Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2267Lung Neoplasms 1050Small Cell Lung Carcinoma 403Adenocarcinoma of Lung 155Mesothelioma, Malignant 120Breast Neoplasms 110Neoplasms 106Brain Neoplasms 101Neoplasm Metastasis 95Melanoma 72Mesothelioma 70NSCLC 69Colorectal Neoplasms 69Adenocarcinoma, Bronchiolo-Alveolar 56Thymoma 53Pancreatic Neoplasms 52Head and Neck Neoplasms 47Ovarian Neoplasms 46Carcinoma, Renal Cell 43Carcinoma 39Stomach Neoplasms 36Prostatic Neoplasms 36Sarcoma 35Esophageal Neoplasms 35Uterine Cervical Neoplasms 34Squamous Cell Carcinoma of Head and Neck 34Adenocarcinoma 34Pleural Effusion, Malignant 33Recurrence 27Urinary Bladder Neoplasms 26

Interventions

efatutazone 1Nivolumab 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Advanced Non-small Cell Lung Cancer (NSCLC) × Thoracic × Clear all
NCT02175017 2024-12-09

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Ono Pharmaceutical Co., Ltd.

Phase 2 Completed
104 enrolled 21 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01101334 2020-06-16

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Completed
90 enrolled 11 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡